Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine - - Full Text View

Sponsor:	Taiho Pharmaceutical Co., Ltd.
Collaborator:	UCB, Inc.
Information provided by:	Taiho Pharmaceutical Co., Ltd.
ClinicalTrials.gov Identifier:	NCT00229424

Purpose

The purpose of the study is to verify superiority of the lafutidine group over the placebo group and non-inferiority to the famotidine group in terms of endoscopic healing rate of the patients with mild reflux oesophagitis.

Furthermore, the followings are compared:

The improvement effect in heartburn and other subjective symptoms, and dosing frequency of MALFA ® suspension (neutralizer) as well as incidence of adverse events among the lafutidine 20 mg/day treatment group, the famotidine 40 mg/day treatment group and the placebo treatment group in patients with mild reflux oesophagitis.

Condition	Intervention	Phase
Gastroesophageal Reflux	Drug: Lafutidine Drug: Famotidine Other: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Active Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	Verification Study on Lafutidine in Mild Reflux Oesophagitis - Double Blind Controlled Study With Famotidine -

Resource links provided by NLM:

MedlinePlus related topics: GERD Heartburn

Drug Information available for: Famotidine Lafutidine

U.S. FDA Resources

Further study details as provided by Taiho Pharmaceutical Co., Ltd.:

Primary Outcome Measures:

Endoscopic healing rate [ Time Frame: At the eighth week after treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Frequency of heartburn symptom, intensity and improvement effect in other subjective symptoms and dosing frequency of MALFA ® suspension (neutralizer) [ Time Frame: Everyday ] [ Designated as safety issue: No ]

Estimated Enrollment:	325
Study Start Date:	April 2005
Study Completion Date:	January 2007
Primary Completion Date:	October 2006 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental Lafutidine group	Drug: Lafutidine Oral administration of lafutidine by 20mg/day along with famotidine placebo
2: Active Comparator Famotidine group	Drug: Famotidine Oral administration of famotidine by 40mg/day along with lafutidine placebo
3: Placebo Comparator Placebo group	Other: Placebo Oral administration of lafutidine placebo along with famotidine placebo

Detailed Description:

In Japan it is reported that many patients with reflux oesophagitis are relatively mild and do not usually require strong treatment, and even H2 receptor antagonists are considered to demonstrate sufficient healing effects. Haruma thinks that the first choice should be PPI in principle which has the best therapeutic effect as the medical guideline if a patient has a strong reflux symptom such as heartburn or is diagnosed with severe reflux oesophagitis (Grade C or D according to the Los Angels Classification) as a result of the upper gastrointestinal endoscopic test. Later, after healing is confirmed at 8 weeks of treatment or after the subjective symptoms have been improved, the dose of PPI should be reduced to half to transfer to maintenance therapy. On the other hand, if a patient has mild subjective symptoms or develops mild reflux oesophagitis (Grade A or B according to the Los Angels Classification) as a result of the upper gastrointestinal endoscopic test, only about 10% of such patients aggravate in the long-run and some patients heal in the natural course. Therefore, considering that Japanese gastric-acid secretion is lower than Westerners, they recommend that antacids such as H2 receptor antagonists or sodium alginates is used to treat symptoms as they appear along with the improvement in the lifestyle. As mentioned above, lafutidine that strongly suppresses acid secretion during the daytime from the initial phase of treatment is expected to demonstrate sufficient effect in treatment of mild reflux oesophagitis similar to the conventional H2 receptor antagonists.

Based on above, the clinical trial is planned with the objective to confirmedly demonstrate the efficacy of lafutidine in mild reflux oesophagitis.

Comparisons: The endoscopic healing rate of lafutidine in the patients with mild reflux oesophagitis is compared to the rate of placebo and it is also compared to the rate of famotidine.

Eligibility

Ages Eligible for Study:	20 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Age 20 and over (at the time of consent given)
Gender and inpatient or outpatient: Irrelevant
Patients diagnosed with Grade A or Grade B mild reflux oesophagitis (according to the Los Angels classification) through endoscopic test
Patients who complained about "heartburn symptom" within one week prior to the enrollment

Exclusion Criteria:

Patients whose "heartburn symptom" has been disappeared (not been observed at all) during the observation period (Check before official enrollment)
Patients in ill compliance with dosing the investigational product for the observation period (Not more than 75%, check from the patient dairy before official enrollment)
Patients the investigator/sub-investigator assessed difficult to complete the patient diary during the treatment period because the patient diary for the observation period has too many deficiencies. (Check before official enrollment)
Patients with complication of gastric/duodenal ulcer (scarring acceptable)
Patients with complication of Barrett lining over the site exceeding 3 cm of esophageal distal portion
Patients who have received the normal dose of H2 receptor antagonist or proton pump inhibitor (PPI) for 8 weeks in vain
Patients whose Helicobacter pylori was successfully eradicated within 24 weeks
Patients with medical history of upper gastrointestinal tract excision
Patients with complication of angina pectoris
Patients who have received treatment of any other investigational product within 12 weeks
Patients who showed any of the following values at the laboratory tests before official enrollment: Hemoglobin: < 9.5 g/dL, WBC: < 3,000/mm^3, Thrombocytes: < 75,000/mm^3, AST and ALT : ≥ 100 IU/L, Creatinine: ≥ 1.5 mg/dL These should be assessed using the current test values from the blood drawn within 4 weeks prior to official enrollment.
Patients with complication of serious cardiac disorder (Grade 3 or above under PAB/SD Notification No. 80) For example, patients with triplet or more ventricular premature contractions (multi-sources) or using a pacemaker
Patients with medical history of serious hypersensitivity to drugs (Grade 3 or above under PAB/SD Notification No. 80)
Patients who receive treatment of cancer
Women of confirmed or potential pregnancy, those who wish to become pregnant, and breast feeding women
Patients having any other condition that, in the opinion of the investigator/sub-investigator disqualifies them for the trial

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00229424

Locations

Japan
Tohoku University Hospital
1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan, 980-8574

Sponsors and Collaborators

Taiho Pharmaceutical Co., Ltd.

UCB, Inc.

Investigators

Principal Investigator:

Tomoyuki Koike, MD

Tohoku University Hospital

More Information

No publications provided

Responsible Party:	Taiho Pharmaceutical Co., Ltd. ( Taiho Pharmaceutical Co., Ltd. )
Study ID Numbers:	10019350, LAF/GER/3D1/FN/01
Study First Received:	September 28, 2005
Last Updated:	January 29, 2010
ClinicalTrials.gov Identifier:	NCT00229424 History of Changes
Health Authority:	Japan: Ministry of Health, Labor and Welfare

Keywords provided by Taiho Pharmaceutical Co., Ltd.:

lafutidine
reflux oesophagitis
Gastroesophageal Reflux
famotidine

Double Blind
Controlled Study
H2 receptor antagonist
H2-blocker

Additional relevant MeSH terms:

Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Gastrointestinal Diseases
Physiological Effects of Drugs
Gastrointestinal Agents
Histamine Agents
Lafutidine
Gastroesophageal Reflux
Histamine H2 Antagonists
Pharmacologic Actions
Esophageal Motility Disorders

Deglutition Disorders
Esophagitis
Esophagitis, Peptic
Digestive System Diseases
Histamine Antagonists
Famotidine
Therapeutic Uses
Anti-Ulcer Agents
Esophageal Diseases
Gastroenteritis
Peptic Ulcer

ClinicalTrials.gov processed this record on February 08, 2010